45 |
Drug Survival and Safety of Biosimilars Compared with Originator Adalimumab for Psoriasis: A Multinational Cohort Study |
Duc Binh Phan, Hugo Jourdain, Miguel Angel Descalzo-Gallego, Alicia González-Quesada, Mahmoud Zureik, Raquel Rivera-DÃaz, Antonio Sahuquillo-Torralba, Mark Lunt, Ignacio Garcia-Doval, Emilie Sbidian, Richard B Warren, Zenas Z N Yiu |
BJD |
2024 |
BJD |
44 |
Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from BADBIR |
Kerry Williams, Georgia Lada, Nick J Reynolds, Kathleen Mcelhone, Ian Evans, Richard B Warren, Shernaz Walton, Olivia Hughes, Anthony Bewley, Kayleigh Mason, C Elise Kleyn on behalf of the BADBIR Study Group |
CED |
2024 |
CED |
43 |
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis |
Ali Al-Janabi; Oras A. Alabas; Zenas Z. N. Yiu; Amy C. Foulkes; Steve Eyre; Adnan R. Khan; Nick J. Reynolds; Catherine H. Smith; Christopher E. M. Griffiths; Richard B. Warren; the BADBIR Study Group. |
JAMA Dermatology |
2023 |
JAMA Dermatology |
42 |
Biosimilars for the Treatment of Psoriasis A Systematic Review of Clinical Trials and Observational Studies |
Duc Binh Phan; Sarah Elyoussfi; Michael Stevenson; Mark Lunt; Richard B. Warren; Zenas Z. N. Yiu |
JAMA Dermatology |
2023 |
JAMA Dermatology |
41 |
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) |
Duc Binh Phan, Anthony P. Bewley, Catherine H. Smith, Teena Mackenzie, Christopher E.M. Griffiths, Mark Lunt, Richard B. Warren, Zenas Z. N. Yiu |
BJD |
2023 |
BJD |
40 |
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) |
Oras A. Alabas, Kayleigh J. Mason, Zenas Z.N. Yiu, Richard B. Warren, Nick Dand, Jonathan N.W.N. Barker, Catherine H. Smith, Christopher E.M. Grifï¬ths, the BADBIR and BSTOP study group |
BJD |
2023 |
BJD |
39 |
Characteristics of "super responders" and "super nonresponders" to first biologic monotherapy for psoriasis: a nested case–control study |
Kayleigh J. Mason, Oras A. Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Jonathan N.W.N. Barker, Zenas Z. N. Yiu, Catherine H. Smith, Christopher E.M. Griffiths, the BADBIR Study Group |
BJD |
2023 |
BJD |
38 |
Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics |
Ali Al-Janabi, Paul Martin, Adnan R. Khan, Amy C. Foulkes, Catherine H. Smith, Christopher E.M. Griffiths, Andrew P. Morris, Steve Eyre, Richard B. Warren, on behalf of the BSTOP Study Group and the BADBIR Study Group |
JACI |
2023 |
JACI |
37 |
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) |
Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths, CEM; BADBIR Study Group |
BJD |
2023 |
BJD |
36 |
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics |
Al-Janabi A, Eyre S, Foulkes AC, Khan AR, Dand N, Burova E, DeSilva B, Makrygeorgou, Davies E, Smith CH, Griffiths CEM, Morris AP, Warren RB; BSTOP & BADBIR Study Groups |
JID |
2023 |
JID |
35 |
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation study from BADBIR |
Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN; BADBIR Study Group |
BJD |
2023 |
BJD |
34 |
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR |
Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group |
BJD |
2023 |
BJD |
33 |
Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using BADBIR |
Lada G, Chinoy H, Talbot PS, Warren RB, Kleyn CE; BADBIR Study Group |
SHD |
2022 |
SHD |
32 |
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis |
Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group |
JAMA Dermatol |
2022 |
JAMA Dermatol |
31 |
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis |
Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups |
J Invest Dermatol |
2022 |
J Invest Dermatol |
30 |
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR |
Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ; Ormerod AD; BADBIR Study Group |
JEADV 2021 |
2021 |
JEADV |
29 |
Defining Trajectories of Response in Psoriasis Patients Treated with Biologic Therapies |
Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN; Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium |
Br J Dermatol 2021 |
2021 |
Br J Dermatol |
28 |
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies |
Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD |
JEADV 2021 |
2021 |
JEADV |
27 |
Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models |
Jalali-Najafabadi F, Stadler M, Dand N, Jadon D, Soomro M, Ho P, Marzo-Ortega H, Helliwell P, Korendowych E, Simpson MA, Packham J, Smith CH, Barker JN, McHugh N, Warren RB, Barton A, Bowes J; BADBIR Study Group; BSTOP Study Group. |
Scientific Reports |
2021 |
Scientific Reports |
26 |
Using Realâ€World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokineticâ€Pharmacodynamic Study |
Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpaâ€Rajah A; Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Andrew Wright, Griffiths CEM, Reynolds NJ,Barker J, Warren RB, Burden AD, Theo Rispens , Joseph F Standing , Catherine H Smith; BADBIR Study Group; BSTOP Study Group; PSORT Consortium |
Clin Transl Sci 2020 |
2020 |
Clin Transl Sci |
25 |
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study |
Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM; BADBIR Study Group |
J Eur Acad Dermatol Venereol 2020 |
2020 |
J Eur Acad Dermatol Venereol |
24 |
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) |
Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN; Burden AD, Smith CH; BADBIR study group and the PSORT consortium |
Br J Dermatol 2020 |
2020 |
Br J Dermatol |
23 |
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology |
Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group |
Br J Dermatol 2020 |
2020 |
Br J Dermatol |
22 |
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) |
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group |
Br J Dermatol 2020 |
2020 |
Br J Dermatol |
21 |
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register |
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group |
JAMA Dermatol 2020 |
2020 |
JAMA Dermatol |
20 |
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis |
Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, CEM Griffiths, Smith CH, Simpson MA, Barker JN; BSTOP Study Group; PSORT Consortium. |
J Allergy Clin Immunol 2019 |
2019 |
J Allergy Clin Immunol |
19 |
Infliximab Is Associated With an Increased Risk of Serious Infection in Patients With Psoriasis in the U.K. And Republic of Ireland: Results From the British Association of Dermatologists Biologic Interventions Register (BADBIR) |
Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BSTOP Study Group |
Br J Dermatol 2019 |
2019 |
Br J Dermatol |
18 |
Development and Validation of a Multivariable Risk Prediction Model for Serious Infection in Patients With Psoriasis Receiving Systemic Therapy |
Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kühl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BSTOP Study Group |
Br J Dermatol 2019 |
2019 |
Br J Dermatol |
17 |
Persistence and effectiveness of non-biologic systemic therapies for moderateâ€toâ€severe psoriasis in adults: a systematic review |
Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM |
Br J Dermatol 2019 |
2019 |
Br J Dermatol |
16 |
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis |
Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A; BSTOP Study Group; PSORT Consortium. |
JAMA Dermatology 2019 |
2019 |
JAMA Dermatology |
15 |
A Standardization Approach to Compare Treatment Safety and Effectiveness Outcomes Between Clinical Trials and Real-World Populations in Psoriasis |
Yiu ZZN, Mason KJ, Barker J, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group |
Br J Dermatol 2019 |
2019 |
Br J Dermatol |
14 |
Differential drug survival of second-line biologic therapies in psoriasis patients: observational cohort study from the British Association of Dermatologists Biologic Interventions Register |
Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, Smith CH, Reynolds NJ, Ashcroft DM, Griffiths CEM; BADBIR Study Group |
J Invest Dermatol 2018 |
2018 |
J Invest Dermatol |
13 |
Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis |
Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K; BADBIR Study Group |
Value Health 2018 |
2018 |
Value Health |
12 |
Risk of Serious Infection in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study From the British Association of Dermatologists Biologic Interventions Register (BADBIR) |
Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group |
J Invest Dermatol 2018 |
2018 |
J Invest Dermatol |
11 |
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR |
Mason KJ, Barker J, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group |
JAMA Dermatology 2018 |
2018 |
JAMA Dermatology |
10 |
Cumulative exposure to biologics and risk of cancer in psoriasis patients: a meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland |
I Garcia-Doval; MA Descalzo; KJ Mason; AD Cohen; AD Ormerod; FJ Gómez-GarcÃa; S Cazzaniga; I Feldhamer; H Ali; E Herrera-Acosta; CEM Griffiths; R Stern; L Naldi; Psonet Network. |
Br J Dermatol 2018 |
2018 |
Br J Dermatol |
9 |
Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength |
Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L; BADBIR Study Group; Psoriasis Stratification to Optimise Relevant Therapy Study Groups |
J Invest Dermatol 2018 |
2018 |
J Invest Dermatol |
8 |
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study |
Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith CH; PSORT Consortium; BADBIR Study Group |
Br J Dermatol 2018 |
2018 |
Br J Dermatol |
7 |
Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) |
Iskandar IYK, Ashcroft DM, Warren RB, Evans I, McElhone K, Owen CM, Burden AD, Smith CH, Reynolds NJ, Griffiths CEM |
Br J Dermatol 2017 |
2017 |
Br J Dermatol |
6 |
Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis |
Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, Reynolds NJ, Griffiths CEM |
Br J Dermatol 2017 |
2017 |
Br J Dermatol |
5 |
Identification of Factors That May Influence the Selection of First-Line Biological Therapy for People With Psoriasis: A Prospective, Multicentre Cohort Study |
Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD, Smith CH, Payne K, Griffiths CEM |
Br J Dermatol 2017 |
2017 |
Br J Dermatol |
4 |
Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis |
Sawyer LM, Wonderling D, Jackson K, Murphy R, Samarasekera EJ, Smith CH |
PharmacoEconomics 2015 |
2015 |
PharmacoEconomics |
3 |
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) |
Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM; Reynolds NJ; Griffiths CEM; BADBIR Study Group |
J Invest Dermatol 2015 |
2015 |
J Invest Dermatol |
2 |
Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register |
Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, McElhone K, Lunt M, Barker JN, Burden AD, Ormerod AD, Reynolds NJ; Smith CH; Griffiths CEM. |
Br J Dermatol 2015 |
2015 |
Br J Dermatol |
1 |
The British Association of Dermatologists Biologic Interventions Register (BADBIR): Design, Methodology and Objectives |
Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CE; BADBIR Study Group. |
Br J Dermatol 2012 |
2012 |
Br J Dermatol |